This study is looking at how well a new medicine called belzutifan works for people with advanced pheochromocytoma, pancreatic neuroendocrine tumors, von Hippel-Lindau disease-associated tumors, advanced gastrointestinal stromal tumors, or other solid tumors with certain genetic changes. The main goal is to see how well the medicine can help patients by measuring their response to treatment.
The trial's ID number is NCT04924075. This is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The study is FDA-regulated and hopes to include about 355 participants.
Who can join
This trial is open to both men and women, 12 years and older. Participants must have a diagnosis of one of the specified advanced tumors or conditions. For certain groups, like those with von Hippel-Lindau disease, participants must be at least 18 years old. The trial team will check to see if someone is eligible.
The study team makes the final call on eligibility.
What happens in the study
Everyone in the trial will receive belzutifan, which is taken as a pill once a day. Participants will continue this treatment until their disease progresses or they choose to stop. There is no random assignment to different groups in this study.
Where
This trial is enrolling at 14 locations. Recruiting sites are listed first.
Cedars-Sinai Medical Center ( Site 0110)
Los Angeles, California
Recruiting
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108)
Baltimore, Maryland
Recruiting
Massachusetts General Hospital ( Site 0111)
Boston, Massachusetts
Recruiting
National Institutes of Health ( Site 0125)
Bethesda, Maryland
Recruiting
Northwestern Medicine Cancer Center - Warrenville ( Site 0134)
Warrenville, Illinois
Recruiting
Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130)
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led global trials in liver and bile duct cancer. Treats pancreatic cancer, gallbladder cancer, bile duct cancer and liver cancer. Offers targeted therapy.
Directs genitourinary oncology at Huntsman Cancer Institute. Treats pancreatic cancer, liver cancer, gallbladder cancer and esophageal cancer. Also treats stomach cancer and colorectal cancer.